Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Ingresos totales | JPY 273.7B | JPY 259.6B | JPY 227.9B | JPY 208.9B |
| Beneficio bruto | JPY 99.1B | JPY 94.7B | JPY 81.4B | JPY 72.7B |
| Ingresos operativos (EBIT) | JPY 23.1B | JPY 23.2B | JPY 17.6B | JPY 5.5B |
| Ingresos netos | JPY 5.2B | JPY 19.0B | JPY 16.2B | JPY 2.2B |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4553. /companies/us/4553
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms